Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...
Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report...
CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand
CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for...
Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies
Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced...
Tianjin University Team Develops Self-Sustaining Na-O2 Battery for Implantable Devices
Researchers at China’s Tianjin University of Technology have made a groundbreaking advancement with the development...
Zai Lab and Novocure Report Positive Phase III Results for TTFields in NSCLC Brain Metastases
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, and Novocure...
Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai
Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China,...
Jiangsu Hengrui Receives NMPA Approval for SHR-7631 ADC Clinical Study in Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...
Acotec Scientific Receives NMPA Approval for Innovative Cardiovascular Devices
Acotec Scientific Holdings Ltd (HKG: 6669), a leading medical device company based in China, has...
Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools
Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China...
WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions
WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Alexion’s Ultomiris Secures FDA Approval for Anti-AQP4 Positive NMOSD Treatment
AstraZeneca’s (AZ; NASDAQ: AZN) rare disease unit, Alexion, has registered its biologic Ultomiris (ravulizumab) with...
NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances
The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...
Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline
AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company...
National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023
The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling...